EHA 2020 | SAL-DaunoDouble trial: 90 mg vs 60 mg daunorubicin in 7+3 induction for AML

Name: SAL-DaunoDouble trial: 90 mg vs 60 mg daunorubicin in 7+3 induction for AML
Uploaded: 2020-06-26T00:00:00Z
Duration: 3 min 41 s
Description: Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, outlines the results from the SAL-DaunoDouble trial comparing 90 mg versus 60 mg in a standard 7+3 induction regimen for newly diagnosed acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Christoph Röllig • 26 Jun 2020

EHA 2020

Acute Myeloid Leukemia Leukemia Daunorubicin

DaunoDouble

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, outlines the results from the SAL-DaunoDouble trial comparing 90 mg versus 60 mg in a standard 7+3 induction regimen for newly diagnosed acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).